Stock 4530 HISAMITSU PHARMACEUTICAL CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hisamitsu Pharmaceutical Co., Inc.

Equities

4530

JP3784600003

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
3,779 JPY +1.86% Intraday chart for Hisamitsu Pharmaceutical Co., Inc. +1.61% -12.34%
Apr. 11 Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 MT
Jan. 12 Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise MT

Valuation

Fiscal Period: February 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 459,348 393,394 542,719 296,969 303,688 286,233 - -
Enterprise Value (EV) 1 330,009 253,240 408,324 156,998 169,115 293,429 286,233 286,233
P/E ratio 23.9 x 21.2 x 58.6 x 30.8 x 25.8 x 21.3 x 17.6 x 16.9 x
Yield 1.5% 1.72% 1.26% 2.3% 2.21% 2.19% 2.38% 2.43%
Capitalization / Revenue 3.2 x 2.79 x 4.74 x 2.47 x 2.37 x 2.07 x 1.87 x 1.81 x
EV / Revenue 3.2 x 2.79 x 4.74 x 2.47 x 2.37 x 2.07 x 1.87 x 1.81 x
EV / EBITDA 16,393,575 x - - - - - - -
EV / FCF -19.5 x 16.6 x 316 x 48.4 x - 58.2 x 75.2 x 20.1 x
FCF Yield -5.12% 6.02% 0.32% 2.07% - 1.72% 1.33% 4.98%
Price to Book 1.84 x 1.59 x 2.15 x 1.15 x 1.16 x 1.11 x 1.06 x 1.03 x
Nbr of stocks (in thousands) 83,518 81,364 81,735 81,139 79,499 75,743 - -
Reference price 2 5,500 4,835 6,640 3,660 3,820 3,779 3,779 3,779
Announcement Date 4/10/19 4/10/20 4/8/21 4/7/22 4/13/23 4/11/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: February 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 143,408 140,992 114,510 120,193 128,330 141,706 153,000 158,000
EBITDA 28,020 - - - - - - -
EBIT 1 22,278 22,727 10,671 9,337 11,599 13,167 15,900 18,500
Operating Margin 15.53% 16.12% 9.32% 7.77% 9.04% 9.29% 10.39% 11.71%
Earnings before Tax (EBT) 1 25,673 26,155 12,197 12,956 16,113 19,186 22,300 22,900
Net income 1 19,204 18,694 9,250 9,658 11,742 13,969 16,300 16,800
Net margin 13.39% 13.26% 8.08% 8.04% 9.15% 9.86% 10.65% 10.63%
EPS 2 230.1 227.6 113.2 118.9 148.0 181.6 215.2 223.3
Free Cash Flow 1 -23,530 23,679 1,716 6,139 - 4,920 3,805 14,266
FCF margin -16.41% 16.79% 1.5% 5.11% - 3.45% 2.49% 9.03%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - 126.67% 18.55% 63.56% - 32.16% 23.34% 84.92%
Dividend per Share 2 82.50 83.00 83.50 84.00 84.50 85.00 90.00 92.00
Announcement Date 4/10/19 4/10/20 4/8/21 4/7/22 4/13/23 4/11/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: February 2020 S1 2021 S1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3 2024 Q1 2024 S1 2024 Q3 2025 Q1 2025 S1 2026 S1
Net sales 1 63,401 52,926 58,551 28,112 26,393 59,619 32,262 32,096 66,977 35,850 36,500 74,000 76,500
EBITDA - - - - - - - - - - - - -
EBIT 1 10,190 5,516 5,706 1,267 519 4,913 3,593 4,361 8,396 3,874 3,400 7,400 8,700
Operating Margin 16.07% 10.42% 9.75% 4.51% 1.97% 8.24% 11.14% 13.59% 12.54% 10.81% 9.32% 10% 11.37%
Earnings before Tax (EBT) 1 10,637 5,515 7,168 1,824 2,398 8,935 4,094 5,712 11,638 5,021 4,000 9,200 10,500
Net income 1 7,548 3,693 5,002 1,216 1,631 6,504 3,018 4,049 8,417 3,693 3,300 7,500 7,600
Net margin 11.91% 6.98% 8.54% 4.33% 6.18% 10.91% 9.35% 12.62% 12.57% 10.3% 9.04% 10.14% 9.93%
EPS 2 91.37 45.22 61.20 14.94 20.46 81.58 37.88 52.09 108.3 48.30 43.60 91.30 93.00
Dividend per Share 41.50 41.75 42.00 - - 42.25 - - 42.50 - - - -
Announcement Date 10/10/19 10/8/20 10/14/21 1/13/22 7/7/22 10/12/22 1/12/23 7/13/23 10/6/23 1/11/24 - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: February 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 129,339 140,154 134,395 139,971 134,573 - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -23,530 23,679 1,716 6,139 - 4,920 3,805 14,266
ROE (net income / shareholders' equity) 7.8% 7.5% 3.7% 3.8% 4.7% 5.4% 6.1% 6.2%
ROA (Net income/ Total Assets) 8.25% 8.47% 3.05% 4.19% 5.2% 6.11% 6.1% -
Assets 1 232,745 220,623 303,627 230,300 225,599 228,455 267,213 -
Book Value Per Share 2 2,982 3,046 3,084 3,172 3,294 3,493 3,553 3,676
Cash Flow per Share 2 299.0 279.0 163.0 172.0 210.0 248.0 221.0 269.0
Capex 1 3,372 3,652 3,573 4,729 7,875 25,000 13,900 5,000
Capex / Sales 2.35% 2.59% 3.12% 3.93% 6.14% 17.54% 9.08% 3.16%
Announcement Date 4/10/19 4/10/20 4/8/21 4/7/22 4/13/23 4/11/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hisamitsu Pharmaceutical Co., Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,779 JPY
Average target price
3,950 JPY
Spread / Average Target
+4.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HISAMITSU PHARMACEUTICAL CO., INC. Stock Hisamitsu Pharmaceutical Co., Inc.
-12.34% 1.82B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4530 Stock
  4. Financials Hisamitsu Pharmaceutical Co., Inc.